FDA Classifies Vitruvias Therapeutics Thyroid Tablet Recall as Highest Risk
The FDA has assigned its highest-risk classification to a recall of Vitruvias Therapeutics' thyroid tablets, USP 30 mg, after tests showed one lot may be stronger than intended. Consumers are advised to check the affected lot, understand potential health risks, and follow FDA guidance regarding the recalled thyroid medicine.
The Economic Times·14h ago